Fig. 4 | npj Breast Cancer

Fig. 4

From: PIK3CA and MAP3K1 alterations imply luminal A status and are associated with clinical benefit from pan-PI3K inhibitor buparlisib and letrozole in ER+ metastatic breast cancer

Fig. 4

Association of MAP3K1, PIK3CA, and Luminal A status with sensitivity to PI3K inhibition in PDX tumors. a Association of buparlisib sensitivity across 170 PDX models, stratified by presence/absence of a MAP3K1 alteration or PIK3CA mutation, or luminal A/B status. P-values represent a one-tailed t-test, with Welch’s correction for unequal variance. b Association of alpelisib sensitivity across 121 PDX models, stratified by presence/absence of a MAP3K1 alteration or PIK3CA mutation, or luminal A/B status. P-values represent a one-tailed t-test, with Welch’s correction for unequal variance

Back to article page